Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended June 30, 2022 and provided operational updates.

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA

Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders. Halper Sadeh encourages Turning Point shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns

TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders

Bristol-Myers

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Turning Point will receive only $76.00 in cash for each share of Turning Point that they own. KSF is seeking to determine whether this consideration and the proces

TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

NEW YORK , June 10, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Turning Point Therapeutics, Inc. (TPTX), relating to its proposed acquisition by Bristol-Meyers Squibb Co. Under the terms of the agreement, TPTX shareholders will receive $76.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/turning-point-therapeutics-inc.

Investor Alert - The M&A Class Action Firm Announces an Investigation of Turning Point Therapeutics, Inc. - TPTX

Wilmington, Delaware--(Newsfile Corp. - June 3, 2022) - Rigrodsky Law, P.A. is investigating Turning Point Therapeutics, Inc. ("Turning Point") (NASDAQ: TPTX) regarding possible breaches of fiduciary duties and other violations of law related to Turning Point's agreement to be acquired by Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the agreement Turning Point's shareholders will receive $76.00 in cash for each share of Turning Point common stock they own.To learn more about this investigation...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout

Turning Point Therapeutics Inc. ( TPTX , Financial) shareholders got a good start to the weekend as the stock soared on news that Bristol-Myers Squibb Co. ( BMY , Financial) is buying the San Diego-based biopharmaceutical company for $76 a share.

Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal

NEW YORK , June 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point Therapeutics, Inc. ("Turning Point" or the "Company") (NASDAQ: TPTX), in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company (NYSE: BMY) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $76.00 in cash for each share of Turning Point common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.

Turning Point Therapeutics Inc (NASDAQ: TPTX) jumped 110% after announcing a definitive merger agreement with Bristol Myers Squibb Co (NYSE: BMY). Under the agreement, Bristol Myers Squibb will acquire Turning Point at $76 per share.

Here is Why Turning Point Therapeutics Jumped 110%

Shares of Turning Point Therapeutics Inc (NASDAQ: TPTX) more than doubled on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biotech company for $4.10 billion in cash. Bristol-Myers to pay $76 a share for TPTX The pharmaceutical giant is paying $76 a share for Turning Point that represents a 116% premium […] The post Turning Point Therapeutics shares more than doubled on Friday appeared first on Invezz.

Turning Point Therapeutics shares more than doubled on Friday

Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY). The post TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics appeared first on InvestorPlace.

TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics

MILWAUKEE , June 3, 2022 /PRNewswire/ -- Ademi LLP is investigating Turning Point Therapeutics (NASDAQ:TPTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myer.  Click here to learn how to join the action: https://www.ademilaw.com/case/turning-point-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Turning Point Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myer

The pharma giant said it would pay $76 a share for the biotech stock, up from Thursday's close of $34.16.

Turning Point Stock Doubles After Bristol Myers Announces Takeover

Bristol Myers Squibb (NYSE: BMY) is buying Turning Point Therapeutics, Inc. (NASDAQ: TPTX) in a $4.1 billion deal. These are the details.

Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal

Shares of Turning Point Therapeutics Inc. TPTX, +2.21% more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical company Bristol Myers Squibb Co. BMY, +0.15% in an all-cash deal valuing Turning Point at about $3.77 billion. Bristol Myers' stock was little changed ahead of the open.

Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion

Bristol Myers Squibb said on Friday it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to its experimental cancer drug.

Bristol Myers to buy Turning Point for $4.1 billion

NEW YORK & SAN DIEGO--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. Turning Point Therapeutics is a clinical-stage pr

Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.

Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided operational updates.

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regulatory designation, and third Breakthrough Therapy designation, to lead drug candidate repotrectinib.

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

SAN DIEGO, SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset.

Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

The volatile stock of Turning Point Therapeutics (NASDAQ: TPTX) is once again piquing the interest of high risk traders after the company announced encouraging data related to a pivotal trial. Whether the stock can climb the roller coaster back above $100 remains to be seen, but a significant inflection point seems to be here.

News for Turning Point Therapeutics Stock (TPTX)